BioHarvest Issues Shareholder Letter and Provides Corporate Update
BioHarvest Sciences (NASDAQ: BHST) released a shareholder letter highlighting key achievements in 2024 and outlook for 2025. The company introduced its new CDMO Services division, partnering with Tate & Lyle for sweetener development. The VINIA® capsule business doubled, with approximately 50,000 active U.S. subscribers and a Q4 2024 run rate of nearly $30 million.
Key developments include the launch of VINIA® Functional Superfood Coffee line, generating $1.6 million in sales since launch, and the acquisition of an 80,000 square foot corporate campus in Yavneh, Israel. Gross margins improved from 44% in Q3 2023 to 56% in Q3 2024, with expectations to exceed 60% in 2025. The company successfully uplisted to Nasdaq and targets adjusted EBITDA profitability in H2 2025.
BioHarvest Sciences (NASDAQ: BHST) ha pubblicato una lettera agli azionisti evidenziando i risultati chiave del 2024 e le prospettive per il 2025. L'azienda ha introdotto la nuova divisione CDMO Services, collaborando con Tate & Lyle per lo sviluppo di dolcificanti. Il business delle capsule VINIA® è raddoppiato, con circa 50.000 abbonati attivi negli Stati Uniti e un tasso annuale per il quarto trimestre 2024 di quasi 30 milioni di dollari.
Sviluppi chiave includono il lancio della linea di caffè funzionale VINIA® Superfood, che ha generato 1,6 milioni di dollari di vendite dal lancio, e l'acquisizione di un campus aziendale di 80.000 piedi quadrati a Yavneh, Israele. I margini lordi sono migliorati dal 44% nel terzo trimestre 2023 al 56% nel terzo trimestre 2024, con aspettative di superare il 60% nel 2025. L'azienda è riuscita a quotarsi con successo al Nasdaq e punta a una redditività di EBITDA rettificato nel secondo semestre del 2025.
BioHarvest Sciences (NASDAQ: BHST) publicó una carta a los accionistas destacando los logros clave en 2024 y las perspectivas para 2025. La empresa presentó su nueva división de Servicios CDMO, asociándose con Tate & Lyle para el desarrollo de edulcorantes. El negocio de las cápsulas VINIA® se duplicó, con aproximadamente 50,000 suscriptores activos en EE. UU. y una tasa anual para el cuarto trimestre de 2024 de casi 30 millones de dólares.
Los desarrollos clave incluyen el lanzamiento de la línea de café funcional VINIA® Superfood, que generó 1.6 millones de dólares en ventas desde su lanzamiento, y la adquisición de un campus corporativo de 80,000 pies cuadrados en Yavneh, Israel. Los márgenes brutos mejoraron del 44% en el tercer trimestre de 2023 al 56% en el tercer trimestre de 2024, con expectativas de superar el 60% en 2025. La empresa logró una cotización exitosa en el Nasdaq y tiene como objetivo la rentabilidad de EBITDA ajustado en la segunda mitad de 2025.
BioHarvest Sciences (NASDAQ: BHST)는 2024년 주요 성과와 2025년 전망을 강조한 주주 서신을 발표했습니다. 회사는 Tate & Lyle과 협력하여 감미료 개발을 위해 새로운 CDMO 서비스 부서를 도입했습니다. VINIA® 캡슐 사업은 두 배로 증가했으며, 미국에서 약 50,000명의 활성 구독자가 있고 2024년 4분기의 연간 수익률은 거의 3천만 달러입니다.
주요 개발 사항으로는 VINIA® 기능성 슈퍼푸드 커피 라인의 출시가 있으며, 출시 이후 160만 달러의 매출을 올렸고, 이스라엘 야브네에 80,000평방피트의 기업 캠퍼스를 인수했습니다. 총 이익률은 2023년 3분기 44%에서 2024년 3분기 56%로 개선되었으며, 2025년에는 60%를 초과할 것으로 기대됩니다. 회사는 Nasdaq에 성공적으로 상장되었으며 2025년 하반기 조정된 EBITDA 수익성을 목표로 하고 있습니다.
BioHarvest Sciences (NASDAQ: BHST) a publié une lettre aux actionnaires mettant en avant les réalisations clés de 2024 et les perspectives pour 2025. L'entreprise a lancé sa nouvelle division de services CDMO, en s'associant avec Tate & Lyle pour le développement de nouveaux édulcorants. L'activité des capsules VINIA® a doublé, atteignant environ 50 000 abonnés actifs aux États-Unis et un taux de revenus annuel de près de 30 millions de dollars pour le quatrième trimestre 2024.
Les développements clés incluent le lancement de la gamme de café fonctionnel VINIA® Superfood, ayant généré 1,6 million de dollars de ventes depuis son lancement, ainsi que l'acquisition d'un campus d'entreprise de 80 000 pieds carrés à Yavneh, en Israël. Les marges brutes sont passées de 44 % au troisième trimestre 2023 à 56 % au troisième trimestre 2024, avec des attentes de dépassement de 60 % en 2025. L'entreprise a réussi son introduction en bourse sur le Nasdaq et vise une rentabilité de l'EBITDA ajusté dans la deuxième moitié de 2025.
BioHarvest Sciences (NASDAQ: BHST) hat einen Aktionärsbrief veröffentlicht, in dem die wichtigsten Errungenschaften für 2024 und die Aussichten für 2025 hervorgehoben werden. Das Unternehmen hat seine neue CDMO-Services-Abteilung vorgestellt und eine Partnerschaft mit Tate & Lyle für die Entwicklung von Süßstoffen eingegangen. Das Geschäft mit VINIA®-Kapseln hat sich verdoppelt, mit etwa 50.000 aktiven Abonnenten in den USA und einer jährlichen Rate für das vierte Quartal 2024 von fast 30 Millionen Dollar.
Zu den wichtigsten Entwicklungen gehören die Einführung der VINIA® Functional Superfood Coffee-Serie, die seit dem Start 1,6 Millionen Dollar Umsatz generiert hat, sowie die Akquisition eines 80.000 Quadratfuß großen Unternehmenscampus in Yavneh, Israel. Die Bruttomargen verbesserten sich von 44% im dritten Quartal 2023 auf 56% im dritten Quartal 2024, mit der Erwartung, 2025 die 60%-Marke zu überschreiten. Das Unternehmen hat erfolgreich einen Platz an der Nasdaq ergattert und strebt in der zweiten Hälfte von 2025 eine EBITDA-Rentabilität an.
- Doubled VINIA® capsule business with 50,000 active U.S. subscribers
- Q4 2024 exit run rate of nearly $30 million
- Gross margin improvement from 44% to 56% year-over-year
- VINIA® coffee line generated $1.6 million since launch
- Strategic partnership with Tate & Lyle for sweetener development
- Acquisition of 80,000 sq ft facility with 4x production capacity potential
- Successfully uplisted to Nasdaq
- Not yet profitable, targeting EBITDA profitability only in H2 2025
Insights
The company's 2024 financial performance and strategic developments warrant attention. Key metrics include US$30 million exit run rate for Q4 2024,
The CDMO partnership with Tate & Lyle represents a significant revenue diversification opportunity, while the new 80,000 sq ft facility could quadruple production capacity. The projected adjusted EBITDA profitability in H2 2025 and the Nasdaq uplisting enhance the company's financial profile and access to capital markets.
The expansion into new product categories (coffee, tea, pods, chews) and growing subscriber base (50,000 active US subscribers) indicate strong commercial execution and market penetration potential.
The Botanical Synthesis technology platform demonstrates significant commercial viability through the Tate & Lyle partnership. The investment in 12 GMP-compliant clean rooms and digitized production processes indicates serious scaling capabilities and regulatory compliance.
The vertical integration strategy with the new Yavneh facility consolidating R&D, manufacturing and corporate operations should drive operational efficiencies. The
The diversification into multiple product delivery formats (capsules, coffee, tea, chews) shows strong market adaptation. The focus on younger, active consumers through new formulations indicates market expansion potential. The dual-track strategy of D2C products and CDMO services creates multiple revenue streams and reduces market risk.
The Nasdaq uplisting should improve stock liquidity and institutional investor access. The pipeline of CDMO opportunities in cosmetics and pharmaceuticals, beyond the Tate & Lyle deal, suggests strong B2B market potential. The commitment to AI integration and molecule discovery capabilities aligns with industry trends toward technological innovation in biotech manufacturing.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 8, 2025) - BioHarvest Sciences Inc., (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel.
Dear Fellow Shareholders,
2024 can be summarized as a year of transformation and growth for BioHarvest, where we introduced our new CDMO Services division - anchored by a partnership with a tier-1 food ingredients producer, Tate & Lyle. We also expect to have effectively doubled our core VINIA® capsule business and successfully brought a new line of VINIA Inside products to market to address a highly incremental consumer base. On the Capital markets front, we achieved a major milestone with our listing on the Nasdaq stock exchange in the U.S., which we expect will support growth by driving enhanced visibility and liquidity amongst U.S. investors.
Each of these major initiatives were the culmination of years of hard work by our growing team, and the fact that they all coincided this year is indicative of the significant acceleration of our business. I am pleased to provide this update on our new CDMO Services division and our rapidly scaling Direct-to-Consumer (D2C) Products divisions, each of which had transformative years in 2024 that we expect will trigger a step change in revenue growth and financial performance in 2025 and beyond.
CDMO Services Division: Solving One of the Industry's Biggest Problems with Botanical Synthesis
The most transformational change in 2024 was the launch of our Contract Development and Manufacturing Organization (CDMO) Services division at the BIO CEO Investor Conference in early March, which coincided with our first non-Deal Road Show of the year in New York City. The addition of our CDMO Business Unit provides us a critical path to accelerate the delivery of the Company's "NORTH STAR" - To discover, develop, manufacture and democratize 5-10 life-changing molecules that will improve the Health & Wellness of millions of people while preserving the planet for generations to come. We now have the ability to partner with industry decision makers by giving them the opportunity to access our Botanical Synthesis technology platform to unlock new solutions for the most significant problems they're facing today. This is a significant addition to our business as it allows us to develop unique molecules for major players in pharmaceuticals, nutraceuticals, cosmetics and nutrition/sweetener industries, which up until today have not been able to be commercialized with other technologies, and that with our Botanical Synthesis Technology, we can produce consistently and economically at large scale.
While we have multiple customers and a robust near-term pipeline, the business is anchored by our recently announced tier-1 partnership with Tate & Lyle, a world leader in ingredient solutions, to develop the next generation of sweeteners using plant-derived molecules. Our partnership with an industry leader such as Tate & Lyle sends a clear message about the maturity of our Botanical Synthesis technology platform and opportunity it presents to the broader industry.
I have spoken throughout the year of the different opportunities that are represented in our CDMO deal pipeline - in addition to our recent Tate & Lyle partnership, we have identified multiple priority opportunities in in both Cosmetics and Pharmaceutical verticals, which are being actively managed in the CDMO deal pipeline, and Zaki and I expect to announce additional CDMO contracts in the first half of 2025.
Not only are our CDMO efforts adding research revenue and potentially lucrative future molecule production agreements, but they are also pivotal in creating our AI assisted molecule discovery capabilities, and in necessitating scaling initiatives that are going to further improve our D2C Products business unit margins.
VINIA® Inside Strategy: Diversifying Our Customer Base through Incremental Delivery Mechanisms
I am very pleased to enter 2025 with approximately 50,000 active subscribers in the USA and a 2024 end-of-year exit run rate of nearly US
As we continue to grow, we will continue to diversify our delivery mechanisms for VINIA® beyond the core capsule business to address a differentiated and incremental customer base. In 2024 we launched the VINIA® Functional Superfood Coffee line, which represented the first VINIA Inside product offering. This strategy is proving to be effective, and as of the end of December 2024 we had sold a cumulative
We are now capitalizing on this momentum with the launch of our VINIA® Functional tea lineup - announced in December 2024 to great response - to be followed by the launch of Nespresso Original compatible coffee pods and VINIA® Functional Tea in K-Cup compatible pods in the first quarter of 2025. The second quarter will see the launch of VINIA SUPER-CHEWS which will contain a "Double Strength Performance Formula" allowing us to better access the critical needs of a younger, more active consumer base including athletes and the military.
Investments in People and Processes Drive Strategic New Capabilities
To support a robust level of growth, we made a series of strategic investments to build new capabilities, strengthening the foundation of our CDMO business and helping to drive better margins in the manufacturing side of our business.
Our acquisition of a new 80,000 square foot corporate campus in Yavneh, Israel will prove transformational, providing a single location where we can consolidate our corporate offices, conduct all CDMO R&D efforts spanning 12 state-of-the-art GMP clean rooms, and expand production capacity up to 4x for production of both VINIA® and of our future olive cell products.
We continue to invest in driving higher efficiencies at every stage of VINIA® production as well, which includes the recent digitization of our entire production process including all biological markers. These initiatives have been transformational to our gross margin profile, which has improved from
This momentum is not possible without quality people, who empower us to achieve all that we do. We added senior horsepower to our Board with the appointment of Ms. Anne Binder, and added domain experts Dr. Itay Mayrose and Dr. Edward Maristany to augment our Artificial Intelligence and Functional Medicine initiatives.
Ultimately, everything we do is a team effort spanning multiple disciplines and I'd like to thank each and every one of our team members for their hard work in 2024, which made our success possible and will empower further growth in 2025.
Successful Uplisting to the Nasdaq Global Market
On the capital markets front, we achieved our long-term goal of uplisting to the Nasdaq, representing a significant capital markets milestone for BioHarvest Sciences and our valued shareholder partners. I am incredibly proud of the efforts of the whole team at BioHarvest, whose operational execution has positioned us to list on a senior U.S. exchange and tap into a global shareholder base.
Ultimately this listing will serve to expand our potential shareholder base to include a wider base of U.S. investors, improve liquidity and elevate our public profile in the industry - ultimately helping to enhance shareholder value creation over the long-term. We have seized this opportunity by attending top investor conferences across the U.S. and have held non-deal roadshows in key financial markets, further bolstering our visibility.
2025 Final Thoughts
Looking ahead, the need for life-changing molecules made possible by our proprietary Botanical Synthesis process will only accelerate. With our new Yavneh corporate campus being established, a burgeoning CDMO services division and ongoing investments in growing our capabilities, we have put the foundation in place to enable continued operational execution in the years to come.
We have the team, technology, intellectual property and operational capabilities all in place to support commercialization at scale and when taken together, we remain confident in our growth prospects and pipeline for 2025 and in our ability to deliver on our target of adjusted EBITDA profitability in the second half of 2025. I look forward to sharing exciting milestones in 2025 and beyond.
Sincerely,
Ilan Sobel
Chief Executive Officer
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is no assurance that the Company will maintain or improve current financial performance, or achieve adjusted EBITDA profitability in 2025, as revenues and margins are dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that new sweetener molecules will be commercialized, as any formulations will need to be tested for product suitability, which will include factors such as taste, after-taste, and affordability. There is no assurance that the Company will ultimately develop 5-10 molecules that will improve the Health & Wellness of millions of people or preserve the planet for generations to come. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond the Company's control. Readers should not place undue reliance on forward-looking statements. The Company does not intend to update forward-looking statement disclosures other than through the Company's management discussion and analysis disclosures available on the Company's profile on SEDAR+ at sedarplus.ca.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236416
FAQ
What is BioHarvest's (BHST) projected revenue run rate for Q4 2024?
How many active VINIA subscribers does BHST have in the USA?
What is BHST's gross margin improvement from Q3 2023 to Q3 2024?
How much revenue has BHST's VINIA® coffee line generated since launch?
When does BHST expect to achieve adjusted EBITDA profitability?
What is the production capacity increase expected from BHST's new Yavneh facility?
